Characterization of TAZ domains important for the induction of breast cancer stem cell properties and tumorigenesis

Cell Cycle

Volumn 14, Issue 1, 2015, Pages 146-156

  Li, Ying Wei ^a   Shen, He ^a   Frangou, Costa ^a   Yang, Nuo ^a   Guo, Jin ^a   Xu, Bo ^a   Bshara, Wiam ^a   Shepherd, Lori ^a   Zhu, Qianqian ^a   Wang, Jianmin ^a   Hu, Qiang ^a   Liu, Song ^a   Morrison, Carl D ^a   Sun, Peiqing ^b   Zhang, Jianmin ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Breast cancer; Cancer stem cells; Hippo pathway; Mammary tumorigenesis; TAZ

Indexed keywords

PROTEIN; TAZ PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TEAD; TRANSCRIPTION FACTOR TEF; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; HIPPO PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA; TEAD1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM CELL; CANCER GENETICS; CANCER PATIENT; CANCER STAGING; CANCER STEM CELL; CELL TRANSFORMATION; CONTROLLED STUDY; FEMALE; FUNCTIONAL GENOMICS; GENETIC FUNCTION ANALYSIS; HIPPO PATHWAY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DEPHOSPHORYLATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MOTIF; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMISTRY; CYTOLOGY; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; MAMMARY GLAND; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; SCID MOUSE; TRANSCRIPTION INITIATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DNA-BINDING PROTEINS; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MAMMARY GLANDS, HUMAN; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84929454867     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2014.967106     Document Type: Article

References (42)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1):57-70.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5):646-674.
3. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012; 21(3):283-296.
4. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012; 10(6):717-728; http://dx.doi.org/10.1016/j.stem.2012. 05.007
5. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010; 19(4):491-505; PMID:20951342; http://dx.doi.org/10.1016/j.devcel. 2010.09.011
6. Halder G, Johnson RL. Hippo signaling: growth control and beyond. Development 2011; 138(1):9-22.
7. Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer 2013; 13 (4):246-257; http://dx.doi.org/10.1038/nrc3458
8. Yu FX, Guan KL. The Hippo pathway: regulators and regulations. Genes Dev 2013; 27(4):355-371.
9. Zhao B, Tumaneng K, Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol 2011; 13(8):877-883; http://dx.doi.org/10.1038/ncb2303
10. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, Xiong Y, Guan, KL. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mole Cell Biol 2008; 28(7):2426-2436; http://dx.doi.org/10.1128/MCB. 01874-07
11. Hao Y, Chun A, Cheung K, Rashidi B, Yang X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem 2008; 283(9):5496-5509.
12. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(b-TRCP). Genes Dev 2010; 24(1):72-85.
13. Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C, Hong W. Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J Biol Chem 2011; 286 (9):7018-7026.
14. Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q, Guan KL. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev 2011; 25 (1):51-63.
15. Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, Hisaminato A, Fujiwara T, Ito Y, Cantley LC, et al. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J 2000; 19(24):6778-6791; PMID:11118213; http://dx.doi.org/10.1093/emboj/ 19.24.6778
16. Walter MA, Spillett DJ, Thomas P, Weissenbach J, Goodfellow PN. A method for constructing radiation hybrid maps of whole genomes. Nat Genet 1994; 7 (1):22-28; http://dx.doi.org/10.1038/ng0594-22
17. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S, et al. Role of YAP/TAZ in mechanotransduction. Nature 2011; 474(7350):179-183.
18. Lai D, Ho KC, Hao Y, Yang X. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res 2011; 71 (7):2728-2738.
19. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011; 147(4):759-772.
20. Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, James JD, Gumin J, Diefes KL, Kim SH, et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 2011; 25(24):2594- 2609.
21. Couzens AL, Knight JD, Kean MJ, Teo G, Weiss A, Dunham WH, Lin ZY, Bagshaw RD, Sicheri F, Pawson T, et al. Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinasephosphatase interactions. Science Signal 2013; 6(302): rs15.
22. Kwon Y, Vinayagam A, Sun X, Dephoure N, Gygi SP, Hong P, Perrimon N. The Hippo signaling pathway interactome. Science 2013; 342(6159):737-740.
23. Wang W, Li X, Huang J, Feng L, Dolinta KG, Chen J. Defining the protein-protein interaction network of the human hippo pathway. Mol Cell Proteomics : MCP 2014; 13(1):119-131; http://dx.doi.org/10.1074/mcp. M113.030049
24. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490 (7418):61-70.
25. Su J, Yoon BJ, Dougherty ER. Accurate and reliable cancer classification based on probabilistic inference of pathway activity. PloS One 2009; 4(12):e8161; http:// dx.doi.org/10.1371/journal.pone.0008161
26. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. New Eng J Med 2010; 363(20):1938- 1948; http://dx.doi.org/10.1056/NEJMra1001389
27. Hong W, Guan KL. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol 2012; 23 (7):785-793.
28. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, Zeng Q, Hong W. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 2008; 68(8):2592-2598.
29. Yang N, Morrison CD, Liu P, Miecznikowski J, Bshara W, Han S, Zhu Q, Omilian AR, Li X, Zhang J. TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle 2012; 11(15):2922-2930.
30. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133 (4):704-715.
31. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011; 331(6024):1559-1564.
32. Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, Xiong Y, Lei QY, Guan KL. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem 2009; 284(20):13355-13362.
33. Liu CY, Zha ZY, Zhou X, Zhang H, Huang W, Zhao D, Li T, Chan SW, Lim CJ, Hong W, et al. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF {b}-TrCP E3 ligase. J Biol Chem 2010; 285 (48):37159-37169.
34. Remue E, Meerschaert K, Oka T, Boucherie C, Vandekerckhove J, Sudol M, Gettemans, J. TAZ interacts with zonula occludens-1 and -2 proteins in a PDZ-1 dependent manner. FEBS Lett 2010; 584(19):4175- 4180.
35. Skibinski A, Breindel JL, Prat A, Galvan P, Smith E, Rolfs A, Gupta PB, Labaer J, Kuperwasser C. The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. Cell Rep 2014; 6(6):1059-1072.
36. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS, Haber DA. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 2006; 103(33):12405-12410; http://dx.doi.org/ 10.1073/pnas.0605579103
37. Zhang J, Ji JY, Yu M, Overholtzer M, Smolen GA, Wang R, Brugge JS, Dyson NJ, Haber DA. YAPdependent induction of amphiregulin identifies a noncell- autonomous component of the Hippo pathway. Nat Cell Biol 2009; 11(12):1444-1450; http://dx.doi. org/10.1038/ncb1993
38. Chan SW, Lim CJ, Huang C, Chong YF, Gunaratne HJ, Hogue KA, Blackstock WP, Harvey KF, Hong W. WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ. Oncogene 2011; 30(5):600-610.
39. Chen HI, Sudol M. TheWWdomain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. Proc Natl Acad Sci U S A 1995; 92 (17):7819-7823; http://dx.doi.org/10.1073/pnas.92. 17.7819
40. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30(3):256-268.
41. Zhao B, Ye X, Yu J, Li L, Li W, Li S, Lin JD, Wang CY, Chinnaiyan AM, Lai ZC, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008; 22(14):1962-1971.
42. Xu B, ThongN, Tan D, Khoury T. Expression of thyroid transcription factor-1 in colorectal carcinoma. Appl Immunohistochem Mol Morphol 2010; 18(3):244-249; http://dx.doi.org/10.1097/PAI.0b013e3181c29407